Share This Post

You are here:

Long, Georgina V., Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, James Larkin, et al. 2017. “Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.” New England Journal of Medicine 0 (0): 0. http://doi.org/10.1056/NEJMoa1708539.

Zurück Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Share This Post

Zur Werkzeugleiste springen